tirzepatide fda approval timeline vs. Retatrutide tirzepatide fda approval timeline BPI

These changes likely result from metabolic shifts and weight loss rather than direct hormonal effects

Ongoing research is focusing on these issues, and it is widely agreed that additional in vivo investigations, particularly studies on chronic exposure and reproductive toxicity, are required to confidently establish comprehensive safety profiles (209, 214)

Retatrutide carries the same mechanism and likely the same risk

insulin glargine The SURPASS-AP-Combo trial enrolled 917 adults with type 2 diabetes (age 18 years, inadequately controlled by previous metformin therapy and insulin-naive), who received tirzepatide 5 mg (n = 230), 10 mg (n = 228), 15 mg (n = 229), or insulin glargine (n = 230)